ACR Concurrent Abstract Session: 2011 Late-breaking Abstracts

Session Type: ACR Late Breaking Abstracts
Tuesday, November 8, 2011: 2:30 PM-4:00 PM
W375c (McCormick Place West)
Talks:
2:30 PM
Mavrilimumab (an Anti-GM-CSFRα Monoclonal Antibody) in Subjects with Rheumatoid Arthritis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Gerd R. Burmester1, Michael E. Weinblatt2, Olga Barbarash3, Mykola Vatutin4, Istvan Szombati5, Rumen Stoilov6, Galina Matsievskaya7, Algirdas Venalis8, Ehsanollah Esfandiari9, Geraldine Grove9, Didier Saurigny9, Matthew A. Sleeman9, Alex Godwood9 and Fabio Magrini9, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3SIH Kemerovo Regional Clinical Hospital, Kemerovo, Russia, 4Donetsk National Medical University, Donetsk, Ukraine, 5Obudai Egészségügyi Centrum, Budapest, Hungary, 6University Multiprofile Hospital for Active Treatment (UMHAT) St. Ivan Rilski EAD, Sofia, Bulgaria, 7City Rheumatology Center, St Petersburg, Russia, 8State Research Institute Innovative Medicines Center, Vilnius, Lithuania, 9MedImmune Ltd, Cambridge, United Kingdom
2:45 PM
Six Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis:  Results From the First Three Years of the FREEDOM Extension
J.P. Brown1, H. G. Bone2, R. Chapurlat3, N. Franchimont4, M. L. Brandi5, E. Czerwinski6, M.-A. Krieg7, Z. Man8, D. Mellström9, S. C. Radominski10, J.-Y. Reginster11, H. Resch12, J. A. Román Ivorra13, C. Roux14, N. S. Daizadeh4, M. L. Geller4, S. Smith4, R.B. Wagman4, S. R. Cummings15 and S. Papapoulos16, 1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2Michigan Bone & Mineral Clinic, Detroit, MI, 3Hôpital Edouard Herriot, Lyon, France, 4Amgen Inc., Thousand Oaks, CA, 5University of Florence, Florence, Italy, 6Krakow Medical Center, Krakow, Poland, 7University Hospital of Lausanne, Lausanne, Switzerland, 8Centro TIEMPO, Buenos Aires, Argentina, 9Sahlgrenska University Hospital, Göteborg, Sweden, 10Universidade Federal do Paraná, Curitiba, Brazil, 11University of Ličge, Ličge, Belgium, 12St. Vincent Hospital, Vienna, Austria, 13Hospital Universitario La Fe, Valencia, Spain, 14Paris Descartes University, Paris, France, 15San Francisco Coordinating Center, CPMC Research Institute, and UCSF, San Francisco, CA, 16Leiden University Medical Center, Leiden, Netherlands
3:00 PM
Oral Calcitonin Demonstrated Symptom-Modifying Efficacy and Decreased Cartilage Volume Loss: Results From a 2-Year Phase 3 Trial in Patients with Osteoarthritis of the Knee
Morten Asser Karsdal1, Peter Alexandersen2, Erik B. Dam3, Juergen Loeffler4, Markus R. John4, Michel Arnold4, Moise Azria4, Inger Byrjalsen1, Bente J. Riis1, Claus Christiansen1 and The CCBR 2301 Investigators5, 1Nordic Bioscience, Herlev, Denmark, 2CCBR, Ballerup, Denmark, 3BiomedIQ, Copenhagen, Denmark, 4Novartis Pharma AG, Basel, Switzerland, 5Ballerup, Denmark
3:15 PM
BCX4208 Combined with Allopurinol Increases Response Rates in Patients with Gout Who Fail to Reach Goal Range Serum Urate on Allopurinol Alone: A Randomized, Double-Blind, Placebo-Controlled Trial
Michael A. Becker1, Alan S. Hollister2, Robert Terkeltaub3, Anita Waugh2, Richard L. Leff4, Amy Flynt5, David Fitz-Patrick6 and William P. Sheridan2, 1University of Chicago Medical Center, Chicago, IL, 2BioCryst Pharmaceuticals, Inc., Durham, NC, 3VA Medical Ctr, San Diego, CA, 4Richard L. Leff MD, LLC, Greater Philadelphia, PA, 5PharPoint Research, Inc., Chapel Hill, NC, 6East-West Medical Research Institute, Honolulu, HI
3:30 PM
Safety and Efficacy of Oral Chemokine Receptor 1 Antagonist CCX354-C in a Phase 2 Rheumatoid Arthritis Study
Paul P. Tak1, Andra Balanescu2, Vira Tseluyko3, Silvia Bojin4, Edit Drescher5, Dan Dairaghi6, Shichang Miao6, Vittorio Marchesin7, Juan Jaen6, Pirow Bekker8 and Thomas J. Schall6, 1EULAR & FOCIS Center of Excellence, AMC/University of Amsterdam, Amsterdam, Netherlands, 2University of Medicine and Pharmacy, Bucharest, Romania, 3City Clinical Hospital, Kharkiv, Ukraine, 4Spitalul Judetean de Urgenta “Dr. Fogolyan Kristof”, Sf. Gheorghe, Romania, 5Veszprém Megyei Csolnoky Ferenc Kórház Nonprofit Zrt., Veszprém, Hungary, 6ChemoCentryx, Inc., Mountain View, CA, 7ChemoCentryx, Mountain View, CA, 8Chemocentryx, Inc., Mountain View, CA
3:45 PM
Efficacy and Safety of Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase III Clinical Trial
Fabrizio De Benedetti1, Hermine Brunner2, Nicolino Ruperto3, Andrew Kenwright4, Clare Devlin4, Inmaculada Calvo3, Ruben Cuttica3, Angelo Ravelli3, Rayfel Schneider2, Despina Eleftheriou3, Carine H. Wouters3, Ricardo Xavier3, Lawrence S. Zemel2, Eileen M. Baildam3, Ruben Burgos-Vargas2, Pavla Dolezalova3, Stella Maris Garay3, Rik Joos3, Alexei Grom2, Nico Wulffraat3, Zbigniew Zuber3, Francesco Zulian3, Alberto Martini3 and Daniel Lovell5, 1IRCCS Ospedale Pediatrico Bambino Gesů, Rome, Italy, 2Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, 3Paediatric Rheumatology International Trials Organization, Genoa, Italy, 4Roche, Welwyn Garden City, United Kingdom, 5Pediatric Rheumatology Collaborative Study Group (PRCSG)
See more of: ACR Late Breaking Abstracts

To see other sessions for this day, use the date buttons to the left.